Jyong Biotech (NASDAQ:MENS) Stock Price Down 4.4% - What's Next?

Key Points

• Jyong Biotech's stock price declined by 4.4% to $45.90 on Monday, significantly below its previous close of $48.00, with trading volumes decreasing by 95% from the average.
• Analyst ratings are mixed; Weiss Ratings maintains a "sell (e+)" rating, while Wall Street Zen upgraded it to a "hold," resulting in an average rating of "sell" for Jyong Biotech.
• The company is focused on developing innovative drugs for urinary system diseases and aims to establish a strong market presence in the U.S., EU, and Asia.

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report)'s share price dropped 4.4% during mid-day trading on Monday . The stock traded as low as $45.90 and last traded at $45.90. Approximately 12,316 shares changed hands during trading, a decline of 95% from the average daily volume of 230,608 shares. The stock had previously closed at $48.00.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on MENS shares. Weiss Ratings restated a "sell (e+)" rating on shares of Jyong Biotech in a research report on Saturday, September 27th. Wall Street Zen upgraded Jyong Biotech to a "hold" rating in a research report on Monday, June 30th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Jyong Biotech presently has an average rating of "Sell".

Jyong Biotech Trading Up 8.4%

The business's 50-day moving average price is $46.43.

About Jyong Biotech

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.